The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...

Memantine selectively improves neural decoding of attended illusory contours, revealing NMDA receptor-dependent enhancement of feedback processing in human visual perception.

Thus, G-protein-coupled receptors can regulate NMDA receptor function indirectly through a PKC-dependent activation of the non-receptor tyrosine kinase (Src) signaling cascade.

The use of combination therapy with a cholinomimetic (AChEI) and a glutamatergic (memantine) agent for the treatment of AD is justified by findings from biochemical studies, and preclinical ...

LA JOLLA, Calif., June 17, 2025 -- (BUSINESS WIRE)-- Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatric diseases, today ...

Memantine was developed from amantadine to increase the dwell time in the NMDA receptor channel. [25, 29] ...

Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease ...

Currently available NMDA receptor blockers do not allow one to distinguish between the effects of Ca 2+ entry directly through NMDA receptor pores and NMDA-dependent activation of VDCCs 12, 13, 14.

Recent findings have also identified anti-NMDA receptor autoantibodies in other neurological and psychiatric diseases such as schizophrenia, depression, bipolar disorder, and dementia.

Amplification of the human epidermal growth factor receptor 2 (HER2, Erb B2) gene leads to persistent activation of signaling pathways that enhance cell proliferation, resistance to apoptosis signals, ...

Recent findings have also identified anti-NMDA receptor autoantibodies in other neurological and psychiatric diseases such as schizophrenia, depression, bipolar disorder, and dementia. Arialys is ...